BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula

Rhea-AI Summary

BioAdaptives (OTCID: BDPT) will open the commercial ordering window for XcellaraHeart™, the flagship product in its new Xcellara™ cellular wellness line, later this week via products.xcellara.com. This follows last week’s buyout and retirement of the company’s largest outstanding convertible commercial debt, which BioAdaptives says strengthens its capital structure and shifts focus to e-commerce execution and DTC revenue growth.

XcellaraHeart™ applies a novel “Supply & Direction” model to support natural cardiovascular repair mechanisms, and is based on the Xcellara™ platform. According to BioAdaptives, its Xcellara™ base formula is supported by a randomized, double-blind, placebo-controlled human clinical trial showing a 268.8% increase in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on over twenty blood parameters. Additional targeted formulations—XcellaraOsteo™, XcellaraNeuro™, and XcellaraDerm™—are planned for late 2026.

Positive

• Largest convertible debt retired, improving capital structure before e-commerce rollout
• Commercial order window for XcellaraHeart™ opens later this week on products.xcellara.com
• Xcellara™ base formula trial showed 268.8% rise in circulating hematopoietic stem and progenitor cells after four weeks
• Planned launch of three additional Xcellara™ formulations in late 2026 for joint, brain, and skin applications

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform

LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new Xcellara™ cellular wellness line, will take place later this week. Customers and distributors will soon be able to place orders directly through products.xcellara.com.

Following last week's successful buyout and retirement of the company's largest convertible commercial debt, BioAdaptives is launching its e-commerce expansion with an enhanced capital structure. The removal of the market overhang allows the company to focus entirely on commercial execution, scale DTC revenues, and drive shareholder value.

"Following the elimination of our largest convertible debt last week, BioAdaptives is in a much stronger operational and financial position," said James Keener, Chief Executive Officer of BioAdaptives®. "We are thrilled to officially open the order window for XcellaraHeart™, marking the commercial debut of our proprietary cellular wellness platform. This is the first of four targeted formulations designed to address multi-billion-dollar markets in active aging and regenerative health. We have cleared our capital runway, finalized our supply chain, and are now fully focused on commercial execution and revenue growth."

XcellaraHeart™ is the commercial application of a novel 'Supply & Direction' model designed to support the body's natural cardiovascular repair mechanisms. The company plans to release three additional targeted formulations on the Xcellara™ platform in late 2026: XcellaraOsteo™ (cartilage and joint health), XcellaraNeuro™ (brain health), and XcellaraDerm™ (skin health).

The full scientific evidence dossier for the XcellaraHeart^™ formulation is accessible at products.xcellara.com/science. It distinguishes between findings from BioAdaptives' human clinical studies on the Xcellara^™ base, published research on Tanshinone IIA, and the company's rationale for combining the two.

MyndSystem^™, MyndMed^™, and MyndRenew^™ are available for purchase at www.MyndSystem.com.

BioAdaptives will release the comprehensive scientific evidence dossier and details on the clinical mechanisms backing the Xcellara™ platform on Tuesday, August 4. For more information and detailed scientific research, visit https://practitioners.Xcellara.com

About BioAdaptives, Inc.

BioAdaptives^® Inc. develops the Xcellara^™ line of supplements that promote stem cell mobilization and tissue targeting. Its flagship product, the Xcellara^™ base formula, is the only dietary supplement backed by a human randomized, double-blind, placebo-controlled clinical trial showing a 268.8% rise in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on over twenty blood parameters. The product line features seven specialized formulas that combine this clinically validated mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress resilience uses. More details are available at products.xcellara.com.

Regulatory Disclaimer

These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart^™, MyndSystem^™, MyndMed^™, and MyndRenew^™ are not intended to diagnose, treat, cure, or prevent any disease. Xcellara^™ is a trademark of BioAdaptives^® Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.

INVESTOR & MEDIA CONTACT

Emily Harrison
EHarrison@BioAdaptives.com
BioAdaptives, Inc.
702-659-8829
X - @BioAdaptivesInc

BioAdaptives^® Inc.
2620 Regatta Dr
Suite 102
Las Vegas, NV 89128
www.bioadaptives.com
products.xcellara.com

SOURCE: BioAdaptives, Inc.

View the original press release on ACCESS Newswire

FAQ

What did BioAdaptives (OTCID: BDPT) announce about XcellaraHeart™ orders on August 3, 2026?

BioAdaptives announced that the commercial ordering window for XcellaraHeart™ will open later this week via products.xcellara.com. According to BioAdaptives, this marks the commercial debut of its Xcellara™ cellular wellness platform, focused on direct-to-consumer e-commerce growth and distributor access.

How does retiring its largest convertible debt affect BioAdaptives (BDPT)?

BioAdaptives reports it has bought out and retired its largest convertible commercial debt, which it says enhances its capital structure. According to BioAdaptives, removing this market overhang allows management to concentrate on commercial execution, scaling direct-to-consumer revenues, and pursuing shareholder value.

What clinical data supports BioAdaptives’ Xcellara™ base formula mentioned in the BDPT update?

According to BioAdaptives, a human randomized, double-blind, placebo-controlled trial of the Xcellara™ base showed a 268.8% rise in circulating hematopoietic stem and progenitor cells after four weeks, with no negative effects on more than twenty blood parameters, supporting its stem cell mobilization claims.

What future Xcellara™ products did BioAdaptives (BDPT) say it plans to launch?

BioAdaptives plans three additional Xcellara™ formulations for late 2026: XcellaraOsteo™ for cartilage and joint health, XcellaraNeuro™ for brain health, and XcellaraDerm™ for skin health. According to BioAdaptives, these extend its targeted cellular wellness platform into multiple active aging markets.

Where can investors find the XcellaraHeart™ scientific evidence dossier from BioAdaptives (BDPT)?

The XcellaraHeart™ scientific evidence dossier is available at products.xcellara.com/science. According to BioAdaptives, it differentiates between its own human clinical findings on the Xcellara™ base, published research on Tanshinone IIA, and the company’s rationale for combining these components in the formulation.

Does BioAdaptives’ Xcellara™ platform have FDA evaluation or disease treatment claims?

According to BioAdaptives, statements about XcellaraHeart™, MyndSystem™, MyndMed™, and MyndRenew™ have not been evaluated by the FDA. The company states these products are not intended to diagnose, treat, cure, or prevent any disease, aligning them with dietary supplement regulatory guidelines.